Skip to Content

Zymeworks Inc Registered Shs When Issued

Rating as of

Company Profile

Business Description

Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.

Contact
1385 West 8th Avenue, Suite 540
Vancouver, BC, V6H 3V9, Canada
T +1 604 678-1388
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 256